Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carolyn Klampe"'
Autor:
Amanika Kumar, Bahaaeldin Youssef, Yi Lin, Martin J. Cannon, Geraldine V. Vijay, Michael P. Gustafson, Michael A. Strausbauch, Michael C. Deeds, Gretchen E. Glaser, Keith L. Knutson, Courtney L. Erskine, Mary L. Solseth, Matthew S. Block, Allan B. Dietz, Carrie L. Langstraat, Carolyn Klampe, Aminah Jatoi, Kevin D. Pavelko, Andrea E. Wahner-Hendrickson, Kimberly R. Kalli, Megan Grudem, Jacob B. Allred, S. John Weroha
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved survival, whereas regulatory T cells predict poorer survival. We previously developed a vaccine whereby patient-derived dendritic cells (DCs) are programmed to induce Th17 respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5d84e73fece13875a906875ca2492f
http://link.springer.com/article/10.1038/s41467-020-18962-z
http://link.springer.com/article/10.1038/s41467-020-18962-z
Autor:
Vonda Wall, Sara Klennert, Carolyn Klampe, Clarissa Polen-De, Sarah A. Kroc, Megan Grudem, Kandelaria M. Rumilla, Amanika Kumar, Myra J. Wick, Casey L. Swanson
Publikováno v:
Gynecologic Oncology. 162:S185-S186
Objectives: Women with epithelial ovarian cancer (EOC) who have a germline mutation, somatic mutation or are found to have homologous recombination deficiency (HRD) have been shown to have an improved survival with use of a PARP inhibitor after compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc41a5079339600651b8c86b2f2008c5
https://doi.org/10.1016/s0090-8258(21)00999-9
https://doi.org/10.1016/s0090-8258(21)00999-9
Autor:
Jill Schimke, Carrie L. Langstraat, Andrea E. Wahner Hendrickson, Joel M. Reid, Aminah Jatoi, Svetomir N. Markovic, Gretchen E. Glaser, Carrie Strand, Wendy K. Nevala, Amanika Kumar, Carolyn Klampe, Vera J. Suman, Heidi D. Finnes, Matthew S. Block, Eleftheria Kalogera, Megan Grudem, Saravut J. Weroha
Publikováno v:
Journal of Clinical Oncology. 38:e18097-e18097
e18097 Background: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (NP) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of vascular-endothelial growth factor (VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa164887748fb0f083e8c7491711bced
https://doi.org/10.1200/jco.2020.38.15_suppl.e18097
https://doi.org/10.1200/jco.2020.38.15_suppl.e18097
Publikováno v:
The American journal of hospicepalliative care. 36(1)
Background: Paclitaxel-treated patients can suffer from years of peripheral neuropathy with pain, numbness, and tingling. Promising preclinical data with poly (ADP-ribose) polymerase (PARP) inhibitors led us to explore this class of agents to palliat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4068f5092e97113adac02d659da11bcc
https://pubmed.ncbi.nlm.nih.gov/29983087
https://pubmed.ncbi.nlm.nih.gov/29983087
Autor:
Smith, Caleb, Hendrickson, Andrea Wahner, Grudem, Megan, Klampe, Carolyn, Deering, Erin, Jatoi, Aminah
Publikováno v:
American Journal of Hospice & Palliative Medicine; Mar2020, Vol. 37 Issue 3, p235-238, 4p